Stocks and Investing
Stocks and Investing
Thu, March 23, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (SPRB) at Strong Buy with Decreased Target to $10 on, Mar 23rd, 2023
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Spruce Biosciences, Inc." (SPRB) at Strong Buy with Decreased Target from $20 to $10 on, Mar 23rd, 2023.
Raghuram has made no other calls on SPRB in the last 4 months.
There are 3 other peers that have a rating on SPRB. Out of the 3 peers that are also analyzing SPRB, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Monday, March 20th, 2023
- Jonathan Wolleben of "JMP Securities" Maintained at Buy and Held Target at $7 on, Friday, March 17th, 2023
- Tiago Fauth of "Credit Suisse" Reiterated at Buy and Held Target at $4 on, Friday, March 17th, 2023
Contributing Sources